Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis

被引：3

作者：

Lloyd-Lavery, A. ^{[1
]}

机构：

[1] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Dept Dermatol, Oxford, England

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 179卷 / 04期

关键词：

CHRONIC PLAQUE PSORIASIS; PHASE-III; EFFICACY;

D O I：

10.1111/bjd.17016

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Linked Article:Valenzuela etal. Br J Dermatol 2018; 179:853-862.

引用

页码：815 / 816

页数：2

共 50 条

[1] Tofacitinib: a new oral Janus kinase inhibitor for psoriasis
Gimenez-Arnau, A. M.
BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (01) : 13 - 14
[2] Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials
Langley, Richard G. B.
Cohen, Arnon D.
Foley, Peter
Griffiths, Christopher E. M.
Lebwohls, Mark
Leonardi, Craig
Winthrop, Kevin
Proulx, James
Rottinghaus, Scott T.
Wolk, Robert
Thompson, John R.
Tatulych, Svitlana
Mallbris, Lotus
Swanson, Robert
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
[3] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study
Lichtenstein, Gary R.
Loftus, Edward V., Jr.
Bloom, Stuart
Lawendy, Nervin
Friedman, Gary S.
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Nduaka, Chudy I.
Su, Chinyu
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S395 - S395
[4] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Wollenhaupt, Juergen
Silverfield, Joel
Lee, Eun Bong
Wood, Susan P.
Terry, Ketti K.
Nakamura, Hiroyuki
Ohno, Yukako
Gruben, David
Benda, Birgitta
Wang, Lisy
Riese, Richard
ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
[5] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Wollenhaupt, Jurgen
Silverfield, Joel C.
Lee, Eun Bong
Wood, Susan P.
Soma, Koshika
Wang, Lisy
Nakamura, Hiroyuki
Komuro, Yoshihiro
Nduaka, Chudi I.
Gruben, David
Benda, Birgitta
Zwillich, Samuel H.
Riese, Richard
Bradley, John D.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S549
[6] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS
Wollenhaupt, J.
Silverfield, J.
Lee, E. B.
Wood, S. P.
Terry, K. K.
Nakamura, H.
Kwok, K.
Anisfeld, A.
Nduaka, C.
Wang, L.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259
[7] Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis
Bagherani, Nooshin
Smoller, Bruce R.
DERMATOLOGIC THERAPY, 2017, 30 (03)
[8] Safety of tofacitinib, an oral Janus kinase inhibitor: integrated data analysis from the global chronic plaque psoriasis clinical trials
Wolk, R.
Langley, R.
Cohen, A.
Foley, P.
Griffiths, C.
Lebwohl, M.
Leonardi, C.
Winthrop, K.
Proulx, J.
Rottinghaus, S.
Thompson, J.
Tatulych, S.
Mallbris, L.
Swanson, R.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 72 - 73
[9] SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: INTEGRATED DATA ANALYSIS FROM THE GLOBAL CHRONIC PLAQUE PSORIASIS CLINICAL TRIALS
Langley, R. G. B.
Cohen, A. D.
Foley, P.
Griffiths, C. E. M.
Lebwohl, M.
Leonardi, C.
Winthrop, K.
Proulx, J.
Rottinghaus, S. T.
Wolk, R.
Thompson, J. R.
Tatulych, S.
Mallbris, L.
Swanson, R.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 253 - 253
[10] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: LONG-TERM EXTENSION STUDY OUTCOMES IN AN AUSTRALIAN RHEUMATOID ARTHRITIS POPULATION
Hall, S.
Nash, P.
Rischmueller, M.
Bossingham, D.
Cook, N.
Witcombe, D.
Kwok, K.
Thirunavukkarasu, K.
INTERNAL MEDICINE JOURNAL, 2014, 44 : 26 - 26

← 1 2 3 4 5 →